Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience DOI Open Access

Jamshid Hamdard,

Mehmet Haluk Yücel, Harun Muğlu

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2937 - 2937

Published: April 24, 2025

Background/Objectives: The goal of this study is to characterize the survival patterns and outcomes women with early-stage breast cancer, a particular emphasis on distinction between HER2-low HER2-zero expression. There limited real-world data how patients HER2-negative or metastatic recurrent cancer are treated. Methods: We retrospectively analyzed medical records 1500 diagnosed January 2020 December 2024. From cohort, 99 34 were included in our analysis. HER2 low was defined as Immunohistochemistry (IHC) 1+ IHC 2+ negative Silver In situ Hybridization (SISH), while zero 0. Statistical analyses, including Kaplan–Meier analyses log-rank tests for group comparisons, performed using IBM SPSS Statistics. Results: median age 55 years. exhibited higher incidence brain, liver, bone, lung metastases (p < 0.001 all) increased use CDK4/6 inhibitors 0.001). univariate younger age, an status, absence associated improved disease-free (DFS) overall (OS). However, multivariate status independently predicted longer DFS (HR = 0.14, 95% CI: 0.05–0.41, p 0.001) OS 0.16, 0.042–0.6, 0.007). Conclusions: Our revealed distinct cancers. Despite burden highlighting their biological heterogeneity need further research inform tailored strategies.

Language: Английский

Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience DOI Open Access

Jamshid Hamdard,

Mehmet Haluk Yücel, Harun Muğlu

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2937 - 2937

Published: April 24, 2025

Background/Objectives: The goal of this study is to characterize the survival patterns and outcomes women with early-stage breast cancer, a particular emphasis on distinction between HER2-low HER2-zero expression. There limited real-world data how patients HER2-negative or metastatic recurrent cancer are treated. Methods: We retrospectively analyzed medical records 1500 diagnosed January 2020 December 2024. From cohort, 99 34 were included in our analysis. HER2 low was defined as Immunohistochemistry (IHC) 1+ IHC 2+ negative Silver In situ Hybridization (SISH), while zero 0. Statistical analyses, including Kaplan–Meier analyses log-rank tests for group comparisons, performed using IBM SPSS Statistics. Results: median age 55 years. exhibited higher incidence brain, liver, bone, lung metastases (p < 0.001 all) increased use CDK4/6 inhibitors 0.001). univariate younger age, an status, absence associated improved disease-free (DFS) overall (OS). However, multivariate status independently predicted longer DFS (HR = 0.14, 95% CI: 0.05–0.41, p 0.001) OS 0.16, 0.042–0.6, 0.007). Conclusions: Our revealed distinct cancers. Despite burden highlighting their biological heterogeneity need further research inform tailored strategies.

Language: Английский

Citations

0